0.71
+7.42%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IRIDEX
From its filings with the US Securities and Exchange Commission
IRIDEX is based in Mountain View, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IRIX. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 3 January 2026, it reported revenue of $52.7m and a net loss of $4.4m. At that date it held total assets of $29.2m and shareholders' equity of $4.9m.
IRIDEX Corporation (“IRIDEX”) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases.
Our proprietary MicroPulse® Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Both technologies are offered as optional treatment modes in select laser consoles in addition to the standard continuous-wave (“CW”) treatment mode. They allow low-energy, subvisible, tissue-sparing laser therapy by different means: MicroPulse technology uses short, microsecond-long laser pulses that allow tissue to cool between pulses giving physicians finer control of thermal elevation to minimize tissue damage. Endpoint Management technology uses a delivery algorithm to titrate the laser energy. CW laser photocoagulation can stabilize vision over the long term but can also result in varying degrees of vision loss. Both MicroPulse and Endpoint Management technologies have demonstrated clinical efficacy with a safer profile compared to standard high-energy CW laser for the treatment of both retinal diseases and glaucoma.
Quoted from its 10-K, filed 2 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 16 Feb 1996
- Employees
- 93
- Website
- iridex.com ↗
- Head office
- 1212 TERRA BELLA AVE, MOUNTAIN VIEW, CA, 94043
- Incorporated in
- DE
- Classification
- Electromedical & Electrotherapeutic Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Scott ShudaIndependent Chairman of the Board$84,756
- Mr. Patrick MercerPresident, Chief Executive Officer, Chief Operating Officer, Director, since 2018$1.1m
- Mr. Romeo DizonChief Financial Officer, since 2025$122,573
- Mr. Bassem BouhabibVice President - International Sales$529,307
- Mr. Yu Hao ChenIndependent Director
- Ms. Beverly HussIndependent Director$52,500
- Mr. William MooreIndependent Director, since 2007$864,466
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IRIDEX Corp is a leading global provider of innovative laser-based medical solutions. Their cutting-edge technology and expertise in ophthalmology have positioned them as a trusted brand in the industry.
- The company's strong intellectual property portfolio gives them a competitive advantage and protects their innovations from being easily replicated by competitors.
- IRIDEX Corp has established a strong distribution network worldwide, enabling them to reach a wide customer base and expand their market presence.
Weaknesses
- The company heavily relies on a limited number of key customers for a significant portion of their revenue, making them vulnerable to changes in customer demand and potential loss of key accounts.
- IRIDEX Corp faces intense competition from well-established players in the medical device industry. Their ability to differentiate themselves and maintain market share can be challenging.
- As a technology-driven company, IRIDEX Corp is exposed to the risk of rapid technological advancements that could render their current products obsolete or less competitive.
Opportunities
- The global demand for minimally invasive medical treatments is growing, presenting an opportunity for IRIDEX Corp to expand their market and offer their advanced laser-based solutions to a broader range of medical specialties.
- Advancements in healthcare infrastructure and access to medical services in emerging markets provide IRIDEX Corp with an opportunity to tap into new geographical regions and increase their customer base.
- The increasing prevalence of ocular diseases, such as glaucoma and diabetic retinopathy, presents a significant market opportunity for IRIDEX Corp to address unmet medical needs and develop targeted treatments.
Threats
- IRIDEX Corp operates in a highly regulated industry, subject to rigorous compliance requirements. Any failure to comply with regulations and standards could result in legal and financial consequences.
- The ongoing COVID-19 pandemic poses a threat to the company's operations, as it has disrupted global healthcare systems and caused delays in elective surgeries, leading to a potential decrease in demand for their products.
- Intense competition and the potential entry of new players in the market pose a threat to IRIDEX Corp's market share and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.